학술논문
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
Document Type
article
Author
Olli Dufva; Matti Kankainen; Tiina Kelkka; Nodoka Sekiguchi; Shady Adnan Awad; Samuli Eldfors; Bhagwan Yadav; Heikki Kuusanmäki; Disha Malani; Emma I Andersson; Paavo Pietarinen; Leena Saikko; Panu E. Kovanen; Teija Ojala; Dean A. Lee; Thomas P. Loughran; Hideyuki Nakazawa; Junji Suzumiya; Ritsuro Suzuki; Young Hyeh Ko; Won Seog Kim; Shih-Sung Chuang; Tero Aittokallio; Wing C. Chan; Koichi Ohshima; Fumihiro Ishida; Satu Mustjoki
Source
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Subject
Language
English
ISSN
2041-1723
Abstract
Aggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-STAT pathway, revealing potential ANKL therapeutic targets.